Merck & Co., Inc. (MSD)

MSD, an international pharmaceutical company, and AKRIKHIN, Russia’s top pharmaceutical manufacturer, announced the localization of production of grazoprevir/elbasvir for the treatment of chronic hepatitis C (CHC) and doravirin/lamivudine/tenofovir for the treatment of HIV.

09 November 2020

In terms of German Merck's output, Nanolek plant in the village of Levintsy, Orichevsky district, is expected to be the world's third after enterprises in France and Greece.

14 December 2018

The total investments of the international biopharmaceutical company MSD, known in several countries as Merck, and Russian R-Pharm to localize the HIV-related drug production in Russia amounted to 200 million rubles, the company said. At the St. Petersburg International Economic Forum, the company announced the completion of the localization of the antiretroviral drug Raltegravir.

03 June 2017

According to Managing Director of the MSD pharmaceuticals company in Russia Leonardo Santarelli, the RF is one of ten priority countries for the company. A day before MSD concluded an agreement at the Saint Petersburg International Economic Forum (SPIEF) with Russian Akrikhin on the launch of full cycle production of four drugs in the Moscow Region, the 360 TV channel announced.

“We work in 140 countries and Russia is one of ten priority countries”, said Santarelli.

18 June 2016

NANOLEK started the production of Merck's Glucophage (metformin). The press release published by the Russian company states that the company scheduled full-cycle medication manufacturing to start in the last six months of 2016.

04 March 2016

Starting late 2015, Nanolek factory will be manufacturing Merck’s Glucophage® and Glucophage Long® for treating type 2 diabetes, and Concor® and Concor® Cor for treating arterial hypertension and heart diseases. It is planned to reach the complete production cycle in the second half of 2016. Investments in the region are projected at EUR 10 million by the end of next year, and the factory’s capacity is expected to reach 1 billion Concor® pills and 400 million Glucophage® pills, which will be enough to meet the requirement of the Russian pharmaceutical market.

01 October 2015
10.9 mln
Moscow region, Kirov region

Investor profile

Merck & Co., Inc. (MSD)


T: 908-740-4000

Public company

Merck is a leading developer and manufacturer of innovative high-quality high-technology products in the pharmaceutical, chemical, and biological industries.